Bortezomib Targets Sp Transcription Factors in Cancer Cells. Karki Ket al. Mol Pharmacol. 2018 Oct. doi: 10.1124/mol.118.112797. [Epub 2018 Aug 16] IRF4 in multiple myeloma-Biology, disease and therapeutic target. Agnarelli A et al. Leuk Res. 2018 Sep. doi: 10.1016/j.leukres.2018.07.025. [Epub 2018 Aug 3] PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism. Zhang H et al. Mol Oncol. 2018 Sep.…
DetailsIxazomib: a novel drug for multiple myeloma. Zanwar S et al. Expert Rev Hematol. 2018 Sep 1. doi: 10.1080/17474086.2018.1518129. [Epub ahead of print] A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. San-Miguel JF et al. Haematologica. 2018 Sep. doi: 10.3324/haematol.2017.185991. [Epub 2018 Jun 28] Phase I study…
DetailsImpact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Cella D et al. Ann Hematol. 2018 Sep 4. doi: 10.1007/s00277-018-3469-4. [Epub ahead of print] Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma. Lee AC et al. J…
DetailsBone Health and Survival in Women With Multiple Myeloma.
Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep. doi: 10.1016/j.clml.2018.06.002. [Epub 2018 Jun 8]
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal. Armoiry X et al. Pharmacoeconomics. 2018 Sep. doi: 10.1007/s40273-018-0644-3. Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. Sivik JM et al. Support Care Cancer. 2018 Sep. doi: 10.1007/s00520-018-4165-6. Surgical thyroparathyroidectomy…
DetailsThe diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma. Jiang Yet al. Oncol Lett. 2018 Sep. doi: 10.3892/ol.2018.9128. [Epub 2018 Jul 11] Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Stolzenburg A et al. Eur J Nucl Med Mol Imaging. 2018 Sep. doi: 10.1007/s00259-018-3997-0. Determining treatment intensity…
DetailsClarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients. Zadik Y. Oral Oncol. 2018 Sep. doi: 10.1016/j.oraloncology.2018.07.016. [Epub 2018 Jul 29.] Proteasome inhibitors for multiple myeloma. Okazuka K and Ishida T. Jpn J Clin Oncol. 2018 Sep 1. doi: 10.1093/jjco/hyy108. The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.…
DetailsEarly salivary changes in multiple myeloma patients undergoing autologous HSCT.
van Leeuwen S et al. Oral Dis. 2018 Sep. doi: 10.1111/odi.12866
Vos JM et al. J Neurol Neurosurg Psychiatry. 2018 Sep. doi: 10.1136/jnnp-2017-316689.
miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1. Jian CM et al. Pathol Res Pract. 2018 Sep. doi: 10.1016/j.prp.2018.07.025. [Epub 2018 Jul 27] Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation‑dependent apoptosis. Zeng C et al. Oncol Rep. 2018 Sep. doi: 10.3892/or.2018.6544.…
DetailsThis month Myeloma UK published a new research report recommending that researchers, the NHS and healthcare professionals work together to improve the way that patient reported outcome measures (PROMs) are utilised in myeloma research. PROMs are questionnaires that are completed by patients and are often used either in a clinical trial setting to measure the impact of a…
Details